Investors in Capricor Therapeutics: A Chance to Join Class Action Lawsuit

In a significant development, Hagens Berman Sobol Shapiro LLP has reached out to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR), urging those who have incurred substantial financial losses to consider participating in a proposed class action lawsuit. The firm aims to gather affected investors and explore potential recoveries following allegations of securities fraud against the company and certain executives.

Understanding the Case Timeline

The lawsuit revolves around events that unfolded between December 17, 2025, and July 26, 2026. During this period, the market saw fluctuations in Capricor's stock price, highlighting the impact of management’s alleged misleading statements regarding the clinical trial data for Deramiocel, a treatment for Duchenne muscular dystrophy (DMD).

On December 3, 2025, Capricor made headlines by announcing positive results from its pivotal Phase 3 HOPE-3 study of Deramiocel. The company's CEO claimed strong evidence that the drug could significantly improve the condition of DMD patients. This announcement triggered a staggering 370% increase in Capricor's stock price, allowing the company to launch a public offering shortly thereafter.

Revelations from the FDA

However, the situation took a drastic turn on July 27, 2026, when the FDA published its briefing document concerning Capricor's resubmitted Biologics License Application (BLA) for Deramiocel. Contrary to the optimistic claims made by Capricor, the FDA highlighted that the clinical trial did not meet its primary efficacy endpoints and revealed undisclosed changes to the statistical analysis plan (SAP) used in the study.

These revelations led to a 64% drop in Capricor's stock price, signaling a loss of investor confidence. The regulatory body's scrutiny raised numerous questions about the Integrity of the data presented by Capricor, prompting Hagens Berman to take action on behalf of shareholders who suffered financial harm during this tumultuous period.

What Investors Should Consider

The firm advises all investors who acquired Capricor securities within the defined class period and feel they have been affected by the alleged fraud to consider their legal options. An important deadline has been set—September 28, 2026—for those interested in being appointed as lead plaintiffs in the class action suit. Even if individuals do not wish to take on this role, they may still have the right to share in any potential recovery.

For those seeking more information, Hagens Berman has established a dedicated website and a contact line to address inquiries regarding the case and the next steps for affected investors. Investors are urged to act promptly to ensure they do not miss out on this opportunity for recovery.

Importance of Timely Action

Investors must recognize the importance of acting quickly. Participating in a class action lawsuit can be a viable path for those who feel wronged, providing an avenue to potentially recover losses sustained during the identified period. Furthermore, whistleblowers with non-public information regarding Capricor are encouraged to come forward, as they may qualify for rewards through the SEC Whistleblower program.

Hagens Berman, a well-respected plaintiffs' rights firm known for its advocacy for corporate accountability, has successfully secured substantial recoveries for investors in similar cases, reinforcing their commitment to those harmed by corporate missteps.

In conclusion, this is a pivotal moment for investors in Capricor Therapeutics, as they grapple with significant losses. The class action lawsuit presents a crucial opportunity for accountability and recovery in light of recent developments and the potential misrepresentation by the company’s leadership.